Showing Latest Articles
Mifamurtide: A Review of its Use in the Treatment of Osteosarcoma
Pediatric Drugs, 06/02/2010
Clinical Article
Frampton JE et al. – In a large, randomized, open–label, multicenter, phase III trial, the addition of adjuvant (postoperative) mifamurtide to three– or four–drug combination chemotherapy (doxorubicin, cisplatin, and high–dose methotrexate with, or without, ifosfamide) was associated with a statistically significant improvement in overall survival in patients with newly diagnosed, high–grade, non–metastatic, resectable osteosarcoma. The pattern of outcome was generally similar in a small cohort of patients with metastatic disease who were enrolled in this trial. Mifamurtide is generally well tolerated; adverse events attributed to administration of the drug include chills, fever, headache, nausea, and myalgias. Based on the available data, mifamurtide can be considered for inclusion in treatment protocols for localized osteosarcoma.